Modifications of Extrinsic Pathway Inhibitor (EPI) and Factor Xa that Affect their Ability to Interact and to Inhibit Factor Vila/Tissue Factor: Evidence for a Two-Step Model of Inhibition

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Thrombosis and Haemostasis

• Publication date

  1988-12-22

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1055/s-0038-1646989PMID 3238648
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action

  1988cited by this paper
• Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains.

  1988cited by this paper
• The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action.

  1988cited by this paper
• Partial purification and characterization of extrinsic pathway inhibitor (the factor Xa-dependent plasma inhibitor of factor VIIa/tissue factor).

  1987cited by this paper
• Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells.

  1987cited by this paper
• Characterization of the inhibition of tissue factor in serum.

  1987cited by this paper
• Affinity purification of human brain tissue factor utilizing factor VII bound to immobilized anti-factor VII.

  1987cited by this paper
• Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation.

  1987cited by this paper
• Activation of human factor VII in the initiation of tissue factor-dependent coagulation.

  1986cited by this paper
• Preparation and properties of derivatives of bovine factor X and factor Xa from which the gamma-carboxyglutamic acid containing domain has been removed.

  1986cited by this paper
• Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site.

  1985cited by this paper
• Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component.

  1985cited by this paper
• Purification of human factor VII utilizing O-(diethylaminoethyl)-Sephadex and Sulfopropyl-Sephadex chromatography.

  1984cited by this paper
• A simplified procedure for purification of human prothrombin, factor IX and factor X.

  1981cited by this paper
• Protein inhibitors of proteinases.

  1980cited by this paper
• Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins.

  1977cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper

• Mutations of TFPI-binding exosites on factor VII cause bleeding phenotypes in factor VII deficiency

  2022cites this paper
• Mechanisms of Hemostasis: Contributions of Platelets, Coagulation Factors, and the Vessel Wall

  2019cites this paper
• Fundamentals of Vascular Biology

  2019cites this paper
• A first‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐06741086, an anti‐tissue factor pathway inhibitor mAb, in healthy volunteers

  2018cites this paper
• Role of exosite binding modulators in the inhibition of Fxa by TFPI

  2015cites this paper
• The role of the different Kunitz domains of TFPI in the down-regulation of the extrinsic coagulation pathway

  2015influential citation
• Inhibition of tissue factor:factor VIIa–catalyzed factor IX and factor X activation by TFPI and TFPI constructs

  2014cites this paper
• Biology of tissue factor pathway inhibitor.

  2014cites this paper
• Normal Coagulation and Hemostasis

  2014cites this paper
• Direct inhibition of factor VIIa by TFPI and TFPI constructs

  2013cites this paper
• Tissue factor pathway inhibitor: structure-function.

  2012influential citation
• inhibitor of heparin: control by antithrombin III and tissue factor pathway Initiation of the tissue factor pathway of coagulation in the presence

  2011cites this paper
• Shwartzman reaction endotoxin-induced intravascular coagulation and the generalized Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to

  2011cites this paper
• The role of TFPI in regulation of TF-induced thrombogenicity on the surface of human monocytes.

  2010cites this paper
• New insights into the clearance of tissue factor pathway inhibitor (TFPI) and unfractionated heparin (UFH)

  2010influential citation
• Plasma tissue factor pathway inhibitor levels in patients with acute pancreatitis

  2009cites this paper
• Hemostasis and Thrombosis in the Surgical Patient

  2006cites this paper
• Opposite circadian rhythms in melatonin and tissue factor pathway inhibitor type 1: does daylight affect coagulation?

  2006cites this paper
• Differences in circadian variations of tissue factor pathway inhibitor type 1 between able-bodied and spinal cord injured.

  2006cites this paper
• The quest for the Holy Grail of tissue factor pathway inhibitor deficiency has just begun

  2005cites this paper
• Coagulation activation in young survivors of myocardial infarction (MI) - a population-based case-control study

  2004influential citation
• endotoxin-induced intravascular coagulation and the generalized Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits

  2003cites this paper
• Poor anticoagulant response to tissue factor pathway inhibitor in patients with venous thrombosis

  2003cites this paper
• Role of the Gla and First Epidermal Growth Factor-like Domains of Factor X in the Prothrombinase and Tissue Factor-Factor VIIa Complexes*

  2003cites this paper
• Probing the interface between factor Xa and tissue factor in the quaternary complex tissue factor-factor VIIa-factor Xa-tissue factor pathway inhibitor.

  2003cites this paper
• Tissue-factor-pathway-Inhibitor: Biochemie, Molekularbiologie, Physiologie und Pathophysiologie

  2002cites this paper
• Tissue factor pathway inhibitor antigen and activity in 96 patients receiving heparin for cardiopulmonary bypass.

  2002cites this paper
• Serum lipids and regulation of tissue factor-induced coagulation in middle-aged men.

  2001cites this paper
• Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis.

  2001cites this paper
• The Role of Catalytic Cleft and Exosite Residues of Factor VIIa for Complex Formation with Tissue Factor Pathway Inhibitor

  2001cites this paper
• Coagulation activation in sepsis.

  2000cites this paper
• Effects of binding of ligand (FVIIa) to induced tissue factor in human endothelial cells.

  2000cites this paper
• Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: low levels of the activated factor X–TFPI complex

  2000cites this paper
• Is Clinical Probability Assessment of Deep Vein Thrombosis by a Score Really Standardized?

  2000cites this paper
• Reduction of factor FVIIa activity during heparin therapy. Evidence for assay interactions with tissue factor pathway inhibitor and antithrombin.

  2000cites this paper
• Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia.

  2000cites this paper
• Physiological Function of Tissue Factor Pathway Inhibitor and Interaction with Heparins

  2000cites this paper
• Heparin Induces Synthesis and Secretion of Tissue Factor Pathway Inhibitor from Endothelial Cells In Vitro

  2000cites this paper
• The TFPI 536C →T Mutation Is not Associated with Increased Risk for Venous or Arterial Thrombosis

  2000cites this paper
• Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin.

  2000cites this paper
• The effect of tissue factor pathway inhibitor on hepatic ischemic reperfusion injury of the rat.

  1999cites this paper
• Low Levels of Heparin-releasable Tissue Factor Pathway Inhibitor in Young Patients with Thrombosis

  1999cites this paper
• High Levels of Tissue Factor Pathway Inhibitor in Patients with Nephrotic Proteinuria

  1999cites this paper
• Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat.

  1999cites this paper
• Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.

  1999cites this paper
• Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor?

  1999cites this paper
• Tissue factor pathway inhibitor (TFPI)

  1999cites this paper
• Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action

  1998cites this paper
• Novel Antithrombotic Strategies

  1998cites this paper
• Monocyte and Haemostasis.

  1998cites this paper
• The effect of cell surface glycosaminoglycans (GAGs) on the inactivation of factor VIIa--tissue factor activity by antithrombin III.

  1998cites this paper
• Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders.

  1998cites this paper
• The Importance of the Binding of Factor Xa to Phospholipids in the Inhibitory Mechanism of Tissue Factor Pathway Inhibitor: The Transmembrane and Cytoplasmic Domains of Tissue Factor Are not Essential for the Inhibitory Action of Tissue Factor Pathway Inhibitor

  1997cites this paper
• Tissue Factor Pathway Inhibitor: Clinical Deficiency States

  1997cites this paper
• Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro.

  1997cites this paper
• Factor Xa Enhances the Binding of Tissue Factor Pathway Inhibitor to Acidic Phospholipids

  1996cites this paper
• Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor.

  1996cites this paper
• Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits.

  1996cites this paper
• Does glycosylation influence the experimental antithrombotic effect of a two-domain tissue factor pathway inhibitor?

  1996cites this paper
• Probable regulation of factor VIIa–tissue factor and prothrombinase by factor Xa–TFPI and TFPI in vivo

  1996cites this paper
• The inhibition of human factor VIIa-tissue factor by antithrombin III-heparin is enhanced by factor X on a human bladder carcinoma cell line.

  1996cites this paper
• Experimental Haemorrhagic Effect of Two-Domain Non-Glycosylated Tissue Factor Pathway Inhibitor Compared to Low Molecular Weight Heparin

  1996cites this paper
• The effect of heparin on the regulation of factor Vila‐tissue factor activity by tissue factor pathway inhibitor

  1996cites this paper
• Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans.

  1996cites this paper
• Lupus anticoagulant and a functional assay for tissue factor pathway inhibitor.

  1996cites this paper
• Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model.

  1996cites this paper
• Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor.

  1996cites this paper
• Coagulation for blood bankers.

  1996cites this paper
• Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and copper-mediated oxidation.

  1995cites this paper
• Regulation of the extrinsic pathway system in health and disease: the role of factor VIIa and tissue factor pathway inhibitor.

  1995cites this paper
• Tissue factor pathway inhibitor: proposed heparin recognition region

  1995cites this paper
• The Tissue Factor Pathway: How It Has Become a “Prima Ballerina”

  1995cites this paper
• Inhibition of Factor X Activation at Extracellular Matrix of Fibroblasts During Flow Conditions: A Comparison Between Tissue Factor Pathway Inhibitor and Inactive Factor VIIa

  1995cites this paper
• The increase with age of the components of the tissue factor coagulation pathway is gender-dependent.

  1995cites this paper
• Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor.

  1995cites this paper
• Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin.

  1994cites this paper
• Synthesis of Tissue Factor Pathway Inhibitor in Human Synovial Cells and Chondrocytes Makes Joints the Predilected Site of Bleeding in Haemophiliacs

  1994cites this paper
• Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparin.

  1994cites this paper
• Antibody-Induced Acute Factor X Deficiency: Clinical Manifestations and Properties of the Antibody

  1994cites this paper
• Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.

  1993cites this paper
• Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis.

  1993cites this paper
• Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complex.

  1993cites this paper
• Antithrombotic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis model.

  1993cites this paper
• The role of tissue factor pathway inhibitor in a revised coagulation cascade.

  1992cites this paper
• Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa.

  1992cites this paper
• Initiation and regulation of tissue factor-dependent blood coagulation.

  1992cites this paper
• The present status of tissue factor pathway inhibitor.

  1992cites this paper
• Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI.

  1991cites this paper
• Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol

  1991cites this paper
• Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction.

  1991cites this paper
• Extrinsic pathway inhibitor--the key to feedback control of blood coagulation initiated by tissue thromboplastin.

  1991cites this paper
• A sulfated rabbit endothelial cell glycoprotein that inhibits factor VIIa/tissue factor is functionally and immunologically identical to rabbit extrinsic pathway inhibitor (EPI).

  1991cites this paper
• The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity.

  1991cites this paper
• Inhibition of Extrinsic Pathway Inhibitor Shortens the Coagulation Time of Normal Plasma and of Hemophilia Plasma

  1991cites this paper
• Regulation of the Tissue Factor Pathway

  1991cites this paper
• Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant.

  1991cites this paper
• The Extrinsic Pathway Inhibitor: A Regulator of Tissue Factor-Dependent Blood Coagulation

  1991cites this paper
• Tissue Factor Pathway Inhibitor

  1991cites this paper
• New Trends in Haemostasis

  1990cites this paper
• Regulation of coagulation by a multivalent Kunitz-type inhibitor.

  1990cites this paper